Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Lowered by Wall Street Zen

Zevra Therapeutics (NASDAQ:ZVRA) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Monday.

ZVRA has been the topic of a number of other reports. Cantor Fitzgerald upped their price target on Zevra Therapeutics from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Thursday, July 10th. Zacks Research cut Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 18th. HC Wainwright began coverage on Zevra Therapeutics in a research report on Wednesday, July 2nd. They issued a “buy” rating and a $26.00 price target on the stock. JMP Securities lowered their price target on Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 13th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Tuesday, October 14th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Zevra Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA opened at $11.10 on Monday. Zevra Therapeutics has a 1-year low of $6.19 and a 1-year high of $13.16. The firm has a market capitalization of $623.04 million, a PE ratio of -52.86 and a beta of 1.49. The business’s 50 day moving average is $9.32 and its 200-day moving average is $9.25. The company has a current ratio of 7.85, a quick ratio of 7.81 and a debt-to-equity ratio of 0.52.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($1.49). Zevra Therapeutics had a net margin of 4.33% and a negative return on equity of 112.40%. The company had revenue of $25.88 million during the quarter, compared to the consensus estimate of $22.49 million. Sell-side analysts predict that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Insiders Place Their Bets

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 19,500 shares of the business’s stock in a transaction on Friday, October 10th. The stock was sold at an average price of $10.82, for a total value of $210,990.00. Following the transaction, the chief executive officer owned 222,016 shares of the company’s stock, valued at approximately $2,402,213.12. The trade was a 8.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John B. Bode acquired 5,000 shares of Zevra Therapeutics stock in a transaction on Tuesday, August 19th. The stock was acquired at an average cost of $9.16 per share, for a total transaction of $45,800.00. Following the purchase, the director owned 45,000 shares of the company’s stock, valued at approximately $412,200. This represents a 12.50% increase in their position. The disclosure for this purchase can be found here. 2.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds have recently added to or reduced their stakes in ZVRA. CWM LLC boosted its holdings in Zevra Therapeutics by 399.5% in the third quarter. CWM LLC now owns 2,872 shares of the company’s stock valued at $27,000 after acquiring an additional 2,297 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Zevra Therapeutics by 30.0% in the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock valued at $49,000 after acquiring an additional 1,280 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Zevra Therapeutics by 20,564.1% in the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock valued at $60,000 after acquiring an additional 8,020 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after acquiring an additional 8,552 shares during the last quarter. Finally, Creative Planning bought a new position in Zevra Therapeutics in the second quarter valued at about $92,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.